



PHONE: 605-773-3495 | FAX: 605-773-5246  
 WEB: [DSS Medicaid Prior Authorizations](#) | EMAIL : [DSSMedicaidpa@state.sd.us](mailto:DSSMedicaidpa@state.sd.us)

## IMAAVY PRIOR AUTHORIZATION REQUEST FORM

This form **MUST BE** submitted with medical records to support services

Date:		
<b>RECEIPIENT INFORMATION</b>		
Medicaid ID:	Date of Birth:	Sex:    M            F
Last Name:		First Name:
<b>GENERAL INFORMATION</b>		
First Date of Service:	Last Date of Service:	
Primary Diagnosis Code:	HCPC Code:	
Drug Name:	Dose & Frequency:	
Hospitalizations/Treatments/Medications Used in the last 6 months:		
<b>POINT OF CONTACT</b>		
Name and Title:		
Email:	Phone:	Fax:
<small><i>Note: The point of contact is the individual completing the PA and would be the contact for questions SD Medicaid may have regarding the PA. The determination notice will be sent to the listed point of contact.</i></small>		
<b>REFERRING PROVIDER INFORMATION</b>		
Name:		
NPI #:	Taxonomy:	
Phone:	Fax:	
<b>SERVICING PROVIDER INFORMATION</b>		
Name:		
Address:		
NPI #:	Taxonomy:	
Phone:	Fax:	

<b>CRITERIA</b>		
<b>Medical records to support use of product are submitted</b>		
<b>Initial Therapy (check one)</b>	<b>Yes</b>	<b>No</b>
	Therapy is requested by or in consultation with a neurologist	
	Individual is ≥ 12 years of age	
	Individual has a documented diagnosis of gMG with labs confirming the presence of <b>one</b> of the following: <ul style="list-style-type: none"> <li>• Anti-AChR antibodies</li> <li>• Anti-MuSK antibodies</li> </ul>	
	Individual has a Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II-IV disease	
	Documentation is submitted indicating the patient's baseline Quantitative Myasthenia Gravis (QMG) score	
	MG-Activities of Daily Living (MG-ADL) total score of ≥6	
	Individual meets previous therapy trials as specified per indication <ul style="list-style-type: none"> <li>• AChR+ Disease(must meet all): <ul style="list-style-type: none"> <li>• Documentation is provided indicating inadequate response or contraindication to pyridostigmine and corticosteroids</li> <li>• Individual has failed treatment with at least 2 immunosuppressive therapies (ex., azathioprine, cyclosporine, mycophenolate, cyclophosphamide, methotrexate, tacrolimus etc.) over the course of the last 12 months OR has failed at least 1 immunosuppressive therapy and required chronic plasmapheresis, plasma exchange (PE) or intravenous immunoglobulin (IVIG)</li> <li>• Documentation is provided indicating previous failure, contraindication or intolerance to inebilizumab (Uplizna)</li> </ul> </li> <li>• MuSK+ Disease (must meet all): <ul style="list-style-type: none"> <li>• Documentation is provided indicating inadequate response or contraindication to corticosteroids</li> <li>• Documentation is provided indicating failure, contraindication or inadequate response to rituximab</li> <li>• Documentation is provided indicating previous failure, contraindication or intolerance to inebilizumab (Uplizna)</li> </ul> </li> </ul>	
	Therapy is not prescribed in combination with other biologics for gMG (e.g. Ultomiris, Zilbrysq, Rystiggo, Vyvgart, Vyvgart Hytrulo, etc.)	
<b>Continuation of Therapy (check one)</b>	<b>Yes</b>	<b>No</b>
	Improvement (reduction in score) in the Myasthenia Gravis-Specific Activities of Daily Living scale (MG-ADL) total score from pretreatment baseline	
	Improvement in the Quantitative Myasthenia Gravis (QMG) total score	
<b>PHYSICIAN SIGNATURE – PROVIDER ONLY</b>		
This form <u>must be</u> signed by a provider		
	I certify that the information given in this form is a true and accurate medical indication for the required product	
<b>Name &amp; Title (Printed):</b>		<b>Specialty:</b>
<b>Signature:</b>		